UMass Medical School researchers to evaluate treatment options for early COVID-19 infection
UMass Medical School Communications July 08, 2021
UMass Medical School is participating in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which is being led by the AIDS Clinical Trials Group (ACTG). ACTIV-2 includes both Phase II and Phase III evaluations of investigational agents for treating early COVID-19.
To qualify for ACTIV-2, participants must have tested positive for SARS-CoV-2 in the outpatient setting within 10 days and started experiencing symptoms within eight days of enrolling.
“The goal of ACTIV-2 is to identify treatments that can keep people who acquire COVID-19 from getting sicker and requiring hospitalization,” said Robert W. Finberg, MD, distinguished professor of medicine and lead investigator of the Medical School’s ACTIV-2 trial site. “People living in central Massachusetts who have recently been diagnosed with COVID-19 a
UMass Medical School studying COVID-19 anti-hospitalization treatments
wbjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wbjournal.com Daily Mail and Mail on Sunday newspapers.
About half of people living with HIV have coronary artery plaque despite low cardiac risk
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
E-Mail
Los Angeles, Calif. - The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced that the Camostat treatment group of the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, will not move to phase 3. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple investigational agents for treating early COVID-19 in a single trial. For information about the trial, please visit the study website.
Camostat, provided by Sagent Pharmaceuticals (a Nichi-Iko Group Company), is an orally administered protease inhibitor that was dosed as 200 mg every six hours for seven days. The Camostat arm of ACTIV-2 completed phase 2 enrollment with 224 participants on April 26, 2021. When the Therapeutic and Prevention Data and Safety Monitoring Board (DSMB) met on June 14, 2021 to review the data and determine whether Camostat would advance to phase 3, they determined that while there were no safet
ACTG announces publication of REPRIEVE sub-study in JAMA Network Open, providing insights into cardiovascular disease risk among people living with HIV
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.